BioSpace News Archive

Immuron Limited is pleased to provide shareholders and the market with a progress update on the US Department of Defense Uniformed Services University Clinical Evaluation of Travelan.

BIOLASE , Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that based on currently available information, preliminary 2022 fourth quarter revenue is expected to be between $14.0 million and $14.4 million, well above 2021 fourth quarter revenue of $12.4 million.

Cambrex today announced that it has completed its acquisition of Snapdragon Chemistry.

Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers in California that the Henry Schein Customer Assistance Hotline is open for dentists and physicians who may experience operational, logistical, or financial issues as a result of damage caused by floods.

bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock.

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its collaboration partner, Life Molecular Imaging (LMI), has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET (positron emission tomography) imaging agent for AD (Alzheimer’s disease).

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL).

Plus Therapeutics, Inc. today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium ( 186 Re) obisbemeda for the treatment of recurrent glioblastoma (GBM).

Avulux is pleased to announce that Axon Optics is now part of the Avulux family.

KemPharm, Inc. announced its partnership with the Hypersomnia Foundation , which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia (IH) and related sleep disorders.